🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT03800017
Recruiting Not applicable

Skeletal Muscle Function in Interstitial Lung Disease

NCT03800017 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2024-08-07
Last updated
2026-05-15

Condition(s) studied

Interstitial Lung DiseaseIdiopathic Pulmonary FibrosisHypersensitivity PneumonitisSclerodermaNonspecific Interstitial Pneumonia

Investigational drug(s) / intervention(s)

Hyperoxia

Hyperoxia: Participants breathe 60% oxygen during exercise

Study summary

Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as well as ability to exercise in ILD patients.

Eligibility

Sex
ALL
Min age
40 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria for ILD Patients: * Age 40-80 years (inclusive) * A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses * Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis * Appropriate candidate for pulmonary rehabilitation * 6 minute walk distance 50m or more * Oxygen saturation ≥ 92% by pulse oximetry at rest while breathing room air * Clinically stable for the preceding 6 weeks * Can fluently read and write in English Inclusion Criteria for Healthy Controls: * Age 40-80 (inclusive) * Normal pulmonary function (80-120% predicted) * No lung or cardiovascular disease * Can fluently read and write in English Exclusion Criteria for the ILD patients: * Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease) * Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation * Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25% * Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program * Use of prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the first study visit * Significant emphysema (less than 10% volume on HRCT or FEV1/FVC less than 0.70) Exclusion Criteria for Healthy Controls: * Currently smoking or previously smoked more than 10 pack-years * Any medical conditions that prevents them for exercising safely * Cardiac pacemaker or any metal or electronic inside the body

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
St. Paul's Hospital Vancouver British Columbia Recruiting

More University of British Columbia trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03800017 on ClinicalTrials.gov ↗ ← All trials in Canada